Compare HLLY & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLLY | LCTX |
|---|---|---|
| Founded | 1903 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.4M | 407.7M |
| IPO Year | N/A | N/A |
| Metric | HLLY | LCTX |
|---|---|---|
| Price | $4.23 | $1.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $4.43 | $4.25 |
| AVG Volume (30 Days) | 906.1K | ★ 1.3M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $598,132,000.00 | $10,816,000.00 |
| Revenue This Year | $1.75 | $6.32 |
| Revenue Next Year | $5.07 | $124.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.05 |
| 52 Week Low | $1.60 | $0.37 |
| 52 Week High | $4.43 | $2.09 |
| Indicator | HLLY | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 42.32 |
| Support Level | $4.05 | $1.63 |
| Resistance Level | $4.31 | $1.77 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 65.08 | 11.36 |
Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.